| |
Tuesday, 5 November 2002 |
|
8:00-9:45 |
Third Plenary Session Willem Burger Zaal C3.2 |
| |
From
Promises of Clinical Trials to Reality
Moderator:
Hubert G.M. Leufkens PhD, Professor of Pharmacoepidemiology, Utrecht
Institute for Pharmaceutical Sciences, University of Utrecht, Utrecht, The
Netherlands
Empirical Evidence on Compliance
Speaker: John Urquhart MD, Professor of
Pharmacoepidemiology, Maastricht University, Maastricht, The Netherlands
A great deal of misinformation prevails about differences between trials and
practice in respect to patient compliance with prescribed or
protocol-specified drug regimens. Sound terminology is based on the
recognition that ambulatory pharmacotherapy has three parts, a beginning, a
middle, and an end, each with qualitatively different dynamics and impact on
therapeutic outcomes. The beginning is the patient’s acceptance, or not, of
the pro-posed drug regimen. If acceptance, which is ~dichotomous, is not
forthcoming, dosing never starts, and so has no attributable outcome. The
middle is the accepting patient’s execution of the prescribed dosing
regimen, which is a continuous process that can vary in quality over time.
The end is the accepting patient’s termination of drug-taking, sometimes
initiated by the prescriber, sometimes by the patient, but in either case
~dichotomous. This presentation will cover each of these phases and their
relationship to compliance and persistence.
Empirical Evidence on Persistence
Speaker: Jacques LeLorier MD, PhD, FRCPC,
Chief, Pharmacocpidemiology & Pharmacoeconomy Research Unit, University of
Montreal, Montreal, Quebec, Canada
We will present the results of our research in adherence with long-term
therapies to treat diabetes with Acarbose and prevent cardiovascular disease
with statins. We will present a work in progress which deals with the
development of a life-table model of the therapeutic effectiveness of the
lipid modifying "statin" drugs in primary prevention. This model is based on
published data collected during a major primary prevention trial of
pravastatin (WOSCOP), but incorporates Quebec’s Ministry of Health
real-world clinical data concerning persistence of patients with statin drug
therapy. The latter data was extracted from the large administrative
database of Quebec’s Ministry of Health. We will show that modelizing the
clinical trial data using real-life persistence on therapy significantly
increases the NNT necessary to obtain a clinical benefit in a real life
population.
The Influence of Side-effects on Effectiveness
Speaker: Dr. Ron Herings, Faculty of Pharmacy,
University of Utrecht, Utrecht, The Netherlands
Panel Discussion
|
|
9:45-10:00 |
Break |
|
10:00-11:00 |
Contributed Podium Presentations
– Session III (4 Concurrent Topics) |
| |
Pharmacoeconomic/health economic, quality-of-life and outcomes research
study results for the following disorders/diseases will be presented |
| |
| Infectious Disease Studies
Session II Willem Burger Zaal C3.2 |
| |
Moderator: Maiwenn J Al PhD, Research Fellow, iMTA, Erasmus
University, Rotterdam, The Netherlands |
|
IN4 |
DISCOUNTING HEALTH BENEFITS: A NOVEL APPROACH TO ENSURE
PROPER VALUING OF VACCINATION STRATEGIES
Bos JM1, van Alphen L2, Postma MJ1
1Groningen University Institute for Drug Exploration (GUIDE), Groningen,
Netherlands; 2National Institute of Public Health and the Environment,
Bilthoven, Netherlands |
|
IN5 |
ECONOMIC EVALUATION OF A LARGE-SCALE MENINGOCOCCAL
C VACCINATION PROGRAM IN THE NETHERLANDS
Welte R1, Postma MJ2, Bos JM3, van Alphen L4
1University of Ulm, Ulm, Germany; 2Groningen University Institute for
Drug Exploration/University of Groningen Research Institute of Pharmacy
(GUIDE/GRIP), Groningen, Netherlands; 3Groningen University Institute
for Drug Exploration (GUIDE), Groningen, Netherlands; 4National
Institute of Public Health and the Environment, Bilthoven, Netherlands |
|
IN6 |
PRIMARY CARE PRESCRIBING AND ANTIBIOTIC
RESISTANCE: WHAT IS THE ADDED VALUE OF PERSON SPECIFIC DATA ABOUT
ANTIBIOTIC PRESCRIBING COMPARED WITH EXISTING, PRACTICE LEVEL
INFORMATION?
Davey PG1, Wei L1, Donnan P1, Clark R2
1University of Dundee, Dundee, United Kingdom; 2Information and
Statistics Division of the Common Services Agency, Edinburgh, United
Kingdom |
|
Migraine/COPD Studies Van Beuningen Zaal C3.5 |
| |
Moderator: Maureen Rutten-van Mölken PhD, Researcher, iMTA, Erasmus
University, Rotterdam, The Netherlands |
|
MC1 |
DEVELOPMENT OF A FUNCTIONAL ASSESSMENT IN
MIGRAINEURS MEASUREMENT TOOL BASED ON THE WHO’S ICIDH2 CLASSIFICATION
Pathak D1, Chisolm D1, Funk-Orsini P2, Mackell J2, Weis KA2
1The Ohio State University, Columbus, OH, USA; 2Pfizer, Inc, New York,
NY, USA |
|
MC2 |
A COST-EFFECTIVENESS ANALYSIS OF ORAL TRIPTAN
THERAPIES
Yalkowsky RB, Malone DC
University of Arizona, Tucson, AZ, USA |
|
MC3 |
PROJECTIONS FOR COPD IN THE NETHERLANDS: HOW THE
TYPE OF PROJECTION AFFECTS THE ESTIMATED GROWTH IN PREVALENCE
Feenstra TL1, van Genugten MM1, Hoogenveen R1, Rutten-van Mölken MP2
1National Institute of Public Health and the Environment (RIVM),
Bilthoven, Netherlands; 2Institute for Medical Technology Assessment,
Rotterdam, Netherlands |
|
Other Diseases/Disorders Studies Van Rijckevorsel Zaal C4.5 |
| |
Moderator: Carin Uyl-de Groot PhD, Researcher, iMTA, Erasmus
University, Rotterdam, The Netherlands |
|
OD1 |
THE COST-EFFECTIVENESS OF RALOXIFENE COMPARED WITH
NO DRUG THERAPY FOR THE PREVENTION OF OSTEOPOROTIC FRACTURES WHEN HRT IS
INAPPROPRIATE: THE CASE OF AUSTRALIA
Davey P1, Lees M1, Graham-Clarke P2
1Medical Technology Assessment Group, Chatswood West, NSW, Australia;
2Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia |
|
OD2 |
LONG-ACTING RISPERIDONE IN SCHIZOPHRENIC PATIENTS
COMPARED WITH ORAL OLANZAPINE AND HALOPERIDOL DECANOATE: A
COST-EFFECTIVENESS ANALYSIS
Llorca PM1, Jasso Mosqueda JG2, Miadi-Fargier H2, Durand-Zaleski I3,
Lançon C4, Casadebaig F5, Philippe A5, Guillon P6, Mehnert A7, Chicoye
A2
1Service de Psychiatrie CHU, Clermont-Ferrand, France; 2Annie Chicoye
Economics, Neuilly sur Seine, France; 3Hôpital Henri Mondor, Paris,
France; 4SHU de Psychiatrie d'Adultes, CHU Ste Marguerite, Marseille,
France; 5INSERM U.513 Faculté de Médecine, Créteil, France;
6Laboratoires Janssen Cilag, Issy les Moulineaux, France; 7Janssen
Pharmaceutica NV, Beerse, Belgium |
|
OD3 |
STOCHASTIC COST-EFFECTIVENESS ANALYSIS OF CHRONIC
VENOUS LEG ULCERS – THE CASE OF PROMOGRAN® IN A SWEDISH HEALTH CARE
SETTING
Ghatnekar O1, Hjelmgren J1, Ödegaard K1, Bjellerup M2
1Swedish Institute for Health Economics, Lund, Sweden; 2Helsingborgs
Lasarett, Helsingborg, Sweden |
|
Inpatient-Related Studies Plate Zaal C4.4 |
| |
Moderator: Elly Stolk MSc, Researcher, iMTA, Erasmus University,
Rotterdam, The Netherlands |
|
HS1 |
COST-EFFECTIVENESS AND BUDGET IMPACT OF THE
SIROLIMUS-ELUTING STENT IN THE STENT ERA
Marchetti M1, Tarricone R2, Lamotte M3, Annemans L4, De Jong P5
1IRCCS Policlinico S.Matteo, Pavia, Italy; 2Università Bocconi, Milan,
Italy; 3HEDM, Meise, Belgium; 4Ghent University, HEDM, Meise, Belgium;
5Cordis J&J, Waterloo, Belgium |
|
HS2 |
COST-EFFECTIVENESS OF LEUKODEPLETION IN MAJOR
CARDIAC SURGERY
Van Hulst M1, Bilgin Y2, Van de Watering L3, Van Oers M2, Brand A3,
Postma M4
1Groningen University Institute for Drug Exploration (GUIDE)/Martini
Hospital, Groningen, Netherlands; 2Amsterdam Medical Centre, Amsterdam,
Netherlands; 3Leiden University Medical Center, Leiden, Netherlands;
4Groningen University Institute for Drug Exploration/University of
Groningen Research Institute of Pharmacy (GUIDE/GRIP), Groningen,
Netherlands |
|
HS3 |
ECONOMIES OF SCALE IN INTENSIVE CARE UNITS
Rapoport J1, Edbrooke D2, Jacobs P3, Dean J2
1Mount Holyoke College, South Hadley, MA, USA; 2Royal Hallamshire
Hospital, Sheffield, United Kingdom; 3Institute of Health Economics,
Edmonton, Alberta, Canada |
|
|
11:00-11:15 |
Break |
|
11:15-12:15 |
Contributed Podium Presentations
– Session IV (4 Concurrent Topics) |
| |
The following topics will be discussed. |
| |
Outcomes Research Methodology Issues – Session II
Willem Burger Zaal C3.2 |
| |
Moderator: Lieven Annemans PhD, Mman, MSc, Director, HEDM and
Professor, Faculty of Medicine, Department of Public Health, Ghent
University, Ghent, Belgium |
|
MD4 |
CHANGES IN COST-EFFECTIVENESS OVER TIME: THE CASE OF
EPOETIN ALFA FOR RENAL REPLACEMENT THERAPY PATIENTS IN THE UK
Remak E1, Hutton J1, Zagari M2
1MEDTAP International, London, UK; 2Ortho-Biotech, UK/Ireland, High
Wycombe, United Kingdom |
|
MD5 |
SHOULD THE EUROQOL DESCRIPTIVE SYSTEM BE EXTENDED
FROM THREE TO FIVE LEVELS? A METHODOLOGICAL STRATEGY WITH AN EMPIRICAL
PILOT
Janssen MF, Bonsel GJ
Academic Medical Centre, Amsterdam, Netherlands |
|
MD6 |
WHAT IS 'TIME' IN TIME PREFERENCE STUDIES?
Meerding WJ, Stuifbergen M, Essink-Bot ML
Erasmus Medical College, University Medical Center Rotterdam, Rotterdam,
Netherlands |
Cross-Cultural Outcomes Research Studies
Van Beuningen Zaal C3.5 |
| |
Moderator: Pawel Sztwiertnia PhD, Chair, ISPOR Polish Chapter &
Deputy Director, Public Sector Financing Department, Ministry of
Finance, Warsaw, Poland |
|
CC1 |
LITERATURE REVIEW OF GUIDELINES FOR CROSS-CULTURAL
ADAPTATION OF HRQL MEASURES: UPDATED RESULTS
Conway K, Mear I, Acquadro C
Mapi Research Institute, Lyon, France |
|
CC2 |
RECOMMENDATIONS ON HRQL/UTILITY DATA IN 14
EUROPEAN PHARMACOECONOMIC GUIDELINES
Szende A1, Rentz A2, Kline Leidy N3
1MEDTAP International, London, England; 2MEDTAP International,
Sindelfingen, Germany; 3MEDTAP International, Inc, Bethesda, MD, USA
|
|
CC3 |
MEASURING POPULATION HEALTH FOR 191 COUNTRIES: WHO
METHODS AND RESULTS
Mathers CD, Salomon J, Murray CJ, Tandon A, Sadana R, Ustun B
World Health Organization, Switzerland, Switzerland |
|
Health Utility Studies - Session II Van Rijckevorsel Zaal
C4.5 |
| |
Moderator: Michael Drummond PhD, Director, Centre for Health
Economics, University of York, York, UK |
|
UT4 |
PATIENT-DERIVED UTILITY ESTMATES OF CHRONIC
HEPATITIS C BASED ON EQ-5D AND RS SCORES
Greiner W1, Ravens-Sieberer U2, Schulz KH3, Sroczynski G4, Wong JB5,
Kuntz KM4, Kallinowski B6, Graf v.d. Schulenburg J-M1, Bullinger M7,
Rossol S8, Siebert U4
1University of Hannover, Hannover, Germany; 2Robert Koch Institut,
Berlin, Germany; 3Universitätsklinikum Eppendorf, Hamburg, Germany;
4Harvard School of Public Health, Boston, MA, USA; 5Tufts University
School of Medicine, Boston, MA, USA; 6University Heidelberg, Heidelberg,
Germany; 7University of Hamburg, Hamburg, Germany; 8University of
Heidelberg, Mannheim, Germany |
|
UT5 |
COMPARISON OF THE SF6D AND THE EQ5D IN PATIENTS
REQUIRING CORONARY REVASCULARISATION
van Stel HF, Buskens E
University Medical Center Utrecht, Utrecht, Netherlands |
|
UT6 |
IMPROVEMENT IN HEALTH UTILITY AMONG RHEUMATOID
ARTHRITIS (RA) PATIENTS TREATED WITH ADALIMUMAB (D2E7), A FULLY HUMAN
ANTI-TNF MONOCLONAL ANTIBODY
van de Putte L1, Boggs R2, Sengupta N2, Dietz B3, Bergemann R4, Rosery
H4, Kupper H3
1University Hospital Nijmegen, Nijmegen, Netherlands; 2Abbott
Laboratories, Abbott Park, IL, USA; 3Abbott GmbH & Co. KG, Ludwigshafen,
Germany; 4Institute for Medical Outcome Research, Lorrach, Germany
|
|
Willingness to Pay Studies Plate Zaal C4.4 |
| |
Moderator: Henri Vanden Baviére MD, MSurg, MBA, FICS, President &
Director, Belgian Institute of Health Economics, Zaventum, Belgium |
|
WP1 |
WILLINGNESS TO PAY FOR PHARMACIST-PROVIDED
MENOPAUSE AND HORMONE REPLACEMENT THERAPY CONSULTATIONS
Branvold AE, Barner J, Vincze G
University of Texas at Austin, Austin, TX, USA |
|
WP2 |
ESTIMATING WILLINGNESS TO PAY FOR DRUGS TO TREAT
ADHD – A CONTINGENT VALUATION STUDY IN STUDENTS
De Ridder A, De Graeve D
University of Antwerp, Antwerpen, Belgium |
|
WP3 |
WILLINGNESS TO PAY FOR A PHARMACIST INTERVENTION
PROGRAM AMONG NON-COMPLIANT DYSLIPIDEMIA PATIENTS
Ali F, Laurin MY, Lariviere C, Tremblay D, Cloutier D
Pfizer Canada Inc, Kirkland, QC, Canada |
|
|
12:15-13:30 |
Lunch,
Exhibits & Contributed Poster Presentations – Session II
Willlem Burger Foyer & Expo Hal |
|
13:30-14:30 |
Issues Panels (4 Concurrent
Panels) |
| |
FROM EFFICACY TO EFFECTIVENESS Van
Rijckevorsel Zaal C4.5
Moderator: Hubert G.M. Leufkens PhD, Professor
of Pharmacoepidemiology, Utrecht Institute for Pharmaceutical Sciences,
University of Utrecht, Utrecht, The Netherlands
Panelists: John Urquhart MD, FRCP(Edin),
Professor of Pharmacoepidmiology, Maastricht University, Maastricht,
The Netherlands; Daniel M Huse MA, Senior Research Scientist, Innovus
Research Inc., Medford, MA, USA;
Thomas R Einarson, Associate Professor, Faculty of Pharmacy, University of
Toronto and Vice President of Scientific Affairs, PharmIdeas Inc., Oakville,
ON, Canada
Bridging the gap between the knowledge on drugs we have from controlled
trials (efficacy) to the real world out there (‘effectiveness’) is a major
challenge for all of us. This panel will provide provocative thinking and
strategies to cope with this gap in order to achieve maximum benefit from
drug treatment.
DISCOUNTING AND ACTUAL TIME PREFERENCE IN
SOCIETY
Van Beuningen Zaal C3.5
Moderator: John Cairns MA, Mphil, Reader,
University of Aberdeen, Aberdeen, Scotland, UK
Panelist: Werner Brouwer MSc, Researcher,
Institute for Medical Technology Assessment, Erasmus University, Rotterdam,
The Netherlands
This session will consider a number of key issues: what do we know about
individual time preferences for future health events; what are the research
priorities with respect to time preferences; and what is the relationship
between individual time preferences for health and appropriate discounting
practice in economic evaluation.
RE-ASSESSMENT OF REIMBURSEMENT STATUS USING
OUTCOMES RESEARCH Willem Burger Zaal C3.2
Moderator: Lieven Annemans PhD, Mman, MSc,
Director, HEDM and Professor, Faculty of Medicine, Department of Public
Health, Ghent University, Ghent, Belgium
Panelists: Ralph Crott PhD, MPH,
Coordinator-Health Economics Unit, European Organization for Research and
Treatment of Cancer (EORTC), Brussels, Belgium; Jens Grueger PhD, Head of
Health Economics Department, Novartis Pharmaceuticals AG, Basel,
Switzerland; Frans Rutten PhD, Professor of Health Economics and Medical
Technology, Erasmus University, Rotterdam, The Netherlands; Dr Colleen Metge,
Faculty of Pharmacy, University of Manitoba, Winnipeg, MB, Canada
Continued coverage of drugs by third payers requires more and more a
re-assessment of their value for money. Many questions rise: which evidence,
methods, timing are required? What is theoretically acceptable and
practically feasible?
WHY SHOULD PHYSICIANS BE INTERESTED IN ECONOMIC
EVALUATIONS? Plate Zaal C4.4
Moderator: Peter Davey MD, FRCP, Head of
Pharmacoeconomics, University of Dundee, Dundee, Scotland, UK
Panelist: Pamela Chavis MD, Associate
Professor, Medical College of Virginia, Department of Ophthalmology, Crozier,
Virginia, USA and Teus Van Barneveld, CBO, Utrecht, The Netherlands
As clinicians’ first interest is in their patients, they may not always be
interested in economic evaluations. Options to bridge the gap between theory
and practice are discussed.
|
|
14:30-15:00 |
Break |
|
15:00-16:00 |
Contributed Workshop
Presentations (7 Concurrent Workshops in 4 Categories) |
| |
SESSION III |
| |
|
Outcomes Research
Methodology Issues |
|
WW17 |
CONJOINT ANALYSIS BY
DESIGN: WHY GIVING RESPONDENTS HARD CHOICES MAKES IT EASIER TO GET GOOD
RESULTS
Hudig Zaal C3.3
Johnson FR1, Backhouse ME2
1Research Triangle Institute, Research Triangle Park, NC, USA; 2Research
Triangle Institute, Manchester, United Kingdom |
|
WW18 |
FEATURES OF GOMPERTZ
FUNCTIONS IN MODELING MORTALITY RATES Plate Zaal C4.4
Wendland G
Consultant, Cologne, Germany |
|
WW19 |
ARE COGNITIVE
HEURISTICS DISTORTING THE RESULTS FROM DISCRETE CHOICE EXPERIMENTS?
Schadee Zaal C3.4
Lloyd AJ1, Cairns J2, van der Pol M3
1MEDTAP International Inc., London, United Kingdom; 2Aberdeen
University, Aberdeen, United Kingdom; 3 University of Calgary, Calgary,
AB, Canada |
|
Cost Study Issues |
|
WW20 |
COMBINING BUDGETARY
IMPACT ANALYSIS AND COST-EFFECTIVENESS ANALYSIS USING DECISION ANALYTIC
MODELING TECHNIQUES Willem Burger Zaal C3.2
Nuijten M1, Mauskopf J2
1MEDTAP International, Inc, Jisp, Netherlands; 2MEDTAP International,
Durham, NC, USA |
|
Quality of Life Study Issues |
|
WW21 |
METHODS AND
CONSIDERATIONS DURING IMPUTATION OF MISSING QOL DATA Ruys
Zaal C4.6
Crawford B1, Massaro J2, Marquis P1, Abetz L3
1Mapi Values, Boston, MA, USA; 2Boston University, Boston, MA, USA;
3Mapi Values, Cheshire, UK |
|
WW14 |
MEASURING HRQOL
USING EQ-5D
Van Rijckevorsel Zaal C4.6
Kind P1, de Charro F2
1Outcomes Research Group, University of York, York, United Kingdom; 2Erasmus
University, Rotterdam, Netherlands |
|
Healthcare Policy Development Issues |
|
WW23 |
DECISION ANALYSIS IN
THE DRUG DEVELOPMENT PROCESS: USE OF PHARMACOECONOMICS TO INFORM
“GO/NO-GO” DECISION MAKING Van Beuningen Zaal C3.5
Thompson D1, Drummond M2
1Innovus Research, Inc, Medford, MA, USA; 2Innovus Research (UK) Ltd.
and University of York, Heslington, United Kingdom |
|
|
